BioCentury
ARTICLE | Clinical News

Empatic zonisamide SR/bupropion SR: Phase IIb data

October 12, 2009 7:00 AM UTC

In the double-blind, U.S. Phase IIb ZB-202 trial in 636 patients, both doses of Empatic met the primary endpoint of significantly increasing weight loss from baseline at 24 weeks vs. zonisamide alone, vs. bupropion alone and vs. placebo. Specifically, mean weight loss was 7.5% for high dose Empatic (360 mg bupropion/360 mg zonisamide), 2.3% for bupropion, 5.3% for zonisamide and 1.4% for placebo. Mean weight loss was 6.1% for low dose Empatic (360 mg bupropion/120 mg zonisamide), 2.3% for bupropion, 3.2% for zonisamide and 1.4% for placebo (p<0.001 for all). ...